Depression is a very common affliction for people who are experiencing cancer and its consequences. I did a search and found a few reports on this topic in relation to caelyx or doxil (liposomal doxorubicin). I have pasted 2 below. One looks at quality of life issues of women with breast cancer ; depression is most severe at the fourth cycle. The other study reports one man's experience with doxil. He lost his taste (ageusia) and became very depressed. His symptoms reversed when he stopped the doxil.
. CASE SUMMARY: A 67-year-old man was diagnosed with multiple myeloma. The disease recurred 18 months later, and renal failure developed. The patient was again treated with the CLAD protocol. After the first cycle, almost complete ageusia occurred, along with weight loss and severe depression. Chemotherapy was continued, but pegylated liposomal doxorubicin was replaced by conventional doxorubicin. Within 12 weeks, the patient's sense of taste returned to normal. , Ann Pharmacother. 2004 Jul-Aug;38(7-8):1212-4. Epub 2004 May 25.
PURPOSE/OBJECTIVES: To identify differences in fatigue, other physical symptoms, and psychological symptoms and their relationship to quality of life (QOL) during chemotherapy and as long as one year after. 25 Caucasian women, aged 40-65 years (-X = 54.3), with stage I or II breast cancer receiving doxorubicin-based chemotherapy. Fatigue levels were moderately intense during treatments and decreased significantly over time. Sleep disturbances and pain were the most frequent, intense, and distressing other physical symptoms. Anxiety was highest at baseline, and depression was highest during the fourth chemotherapy treatment. Fatigue was correlated with other physical and psychological symptoms at some times during treatments and consistently following treatments. Higher fatigue was associated with lower QOL in several domains. CONCLUSIONS: Fatigue is associated with other physical and psychological symptoms that fluctuate during and after treatment. Higher fatigue compromises QOL. IMPLICATIONS FOR NURSING: Interventions targeting primary or cluster symptoms can reduce the impact of adjuvant chemotherapy on fatigue, other symptoms, and QOL. Oncol Nursing Forum 2006 Jan 1;33(1):E18-26.